Presentations held at Photocure ASA's Capital Markets Day

Please find enclosed the presentations that will be held at Photocure ASA's Capital Markets Day,  28th October 2009:



The presentations start at 12:30 CET and will be held at Shippingklubben in Oslo, Norway.

For further information, please contact:

President and CEO Kjetil Hestdal
Mobile: +47 913 19 535
Office: +47 22 06 22 10

CFO Christian Fekete
Mobile: +47 916 42 938
Office: +47 22 06 22 10

About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.

Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing to leading pharmaceutical companies on a regional or global basis prior to phase III.

Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU and under priority review by FDA in the US. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM) platform.

For more information about Photocure, visit our website at